A common genetic variation in the COMT gene may modify the cardiovascular benefit of aspirin, and in some people, may confer slight harm, a new study suggests. Aspirin is currently the gold standard for antiplatelet therapy and a daily low-dose aspirin is widely prescribed for the prevention of cardiovascular disease.